(Q36651446)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23339116%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

title

Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23339116%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23339116%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Derralynn A Hughes

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23339116%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Ari Zimran

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23339116%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Gregory M Pastores

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23339116%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Deborah Elstein

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23339116%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Rebecca Mardach

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23339116%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Christine Eng

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23339116%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Laurie Smith

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23339116%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Margaret Heisel-Kurth

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23339116%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Joel Charrow

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23339116%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Paul Harmatz

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23339116%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Paul Fernhoff

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23339116%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

William Rhead

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23339116%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Nicola Longo

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23339116%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Pilar Giraldo

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23339116%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Juan A Ruiz

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23339116%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

David Zahrieh

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23339116%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Eric Crombez

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23339116%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Gregory A Grabowski

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23339116%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

22 January 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23339116%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Hematology

22 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23339116%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

88

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23339116%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23339116%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

172-178

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23339116%20AND%20SRC:MED&resulttype=core&format=json

Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease

22 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586535

Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586535

Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586535

Characterization of gene-activated human acid- -glucosidase: Crystal structure, glycan composition, and internalization into macrophages

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586535

The long-term international safety experience of imiglucerase therapy for Gaucher disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586535

Therapeutic goals in the treatment of Gaucher disease.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586535

Nucleotide sequence of cDNA containing the complete coding sequence for human lysosomal glucocerebrosidase.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586535

Management of neutralizing antibody to Ceredase in a patient with type 3 Gaucher disease.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586535

A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586535

Transglycosidase activity of chitotriosidase: improved enzymatic assay for the human macrophage chitinase.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586535

Enzyme therapy of gaucher disease: clinical and biochemical changes during production of and tolerization for neutralizing antibodies.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3586535

Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention

20 September 2018

1 reference

12 December 2020

Replacement therapy with imiglucerase for type 1 Gaucher's disease

1 reference

12 December 2020

Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration

1 reference

12 December 2020

Monitoring of Gaucher patients with a novel chitotriosidase assay

1 reference

12 December 2020

A pharmacokinetic analysis of a novel enzyme replacement therapy with Gene-Activated human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease

1 reference

12 December 2020

A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1

1 reference

12 December 2020

Guidelines for the restart of imiglucerase in patients with Gaucher disease: recommendations from the European Working Group on Gaucher disease

1 reference

12 December 2020

Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources

1 reference

12 December 2020

Identifiers

DOI

10.1002/AJH.23383

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23339116%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23339116%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

PubMed publication ID

23339116

1 reference